With its bevy of drug delivery platforms and recent success in Big Pharma partnerships, IntelGenx ($IGXT) is looking to duplicate the success of Biovail, CEO Horst Zerbe said. As Seeking Alpha reports, Zerbe said he's modeling IntelGenx's moves on the company that has since merged with Valeant Pharmaceuticals ($VRX), saying that his firm next needs to develop its own contract research and manufacturing operation, as most manufacturers struggle to produce high-tech platforms like IntelGenx's VersaFilm. Report